The Food and Drug Administration recently approved Kisqali as a once-daily oral therapy for use in combination with an aromatase inhibitor. It is for postmenopausal women who have advanced or metastatic breast cancer that is hormone receptor–positive and human epidermal growth factor receptor 2–negative.
“The diagnosis of advanced or metastatic breast cancer has a devastating impact on patients, as well as their loved ones,” said Paul Urick, Diplomat president. “Kisqali is a groundbreaking new treatment that can improve quality of life for our patients.”
According to the American Cancer Society, breast cancer is the second most common cancer among American women, with more than 315,000 diagnoses expected in 2017.
Diplomat serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: Take good care of patients and the rest falls into place.
.jpg)
1.png)
